Group 1 - Candel Therapeutics, Inc. (CADL) closed at 21 suggests a 311% upside potential [1] - The average price targets range from a low of 25, with a standard deviation of $4.90, indicating a variability in estimates; the lowest estimate suggests a 193.5% increase, while the highest indicates a 389.2% upside [2] - Analysts show strong agreement on CADL's ability to report better earnings than previously predicted, which supports the view of potential upside [4][11] Group 2 - Over the last 30 days, the Zacks Consensus Estimate for CADL's current year earnings has increased by 17.5%, with one estimate moving higher and no negative revisions [12] - CADL holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating a strong potential for upside in the near term [13]
Wall Street Analysts Predict a 310.96% Upside in Candel Therapeutics (CADL): Here's What You Should Know